Parkinson’s Disease Overview
Parkinson’s disease (PD) is a neurodegenerative disorder that affects predominately dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra.
“Parkinson’s Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson’s Disease Market.
The Parkinson’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Parkinson’s Disease Pipeline Report:
Route of Administration
Parkinson’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Molecule Type
Products have been categorized under various Molecule types, such as
Parkinson’s Disease Pipeline Therapeutics Assessment
DelveInsight’s Parkinson’s Disease Report covers around 150+ products under different phases of clinical development like-
Some of the key companies in the Parkinson’s Disease Therapeutics Market include:
Key companies developing therapies for Parkinson’s Disease treatment are – Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others.
Emerging Parkinson’s Disease Drugs Under Different Phases of Clinical Development Include:
Get a Free Sample PDF Report to know more about Parkinson’s Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights
Parkinson’s Disease Pipeline Analysis:
The Parkinson’s Disease pipeline report provides insights into
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Parkinson’s Disease product details are provided in the report. Download the Parkinson’s Disease pipeline report to learn more about the emerging Parkinson’s Disease therapies
Parkinson’s Disease Pipeline Market Drivers
Parkinson’s Disease Pipeline Market Barriers
Scope of Parkinson’s Disease Pipeline Drug Insight
Request for Sample PDF Report for Parkinson’s Disease Pipeline Assessment and clinical trials
Table of Contents
1
Parkinson’s Disease Report Introduction
2
Parkinson’s Disease Executive Summary
3
4
Parkinson’s Disease- Analytical Perspective In-depth Commercial Assessment
5
Parkinson’s Disease Pipeline Therapeutics
6
Parkinson’s Disease Late Stage Products (Phase II/III)
7
Parkinson’s Disease Mid Stage Products (Phase II)
8
Parkinson’s Disease Early Stage Products (Phase I)
9
Parkinson’s Disease Preclinical Stage Products
10
Parkinson’s Disease Therapeutics Assessment
11
Parkinson’s Disease Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Parkinson’s Disease Key Companies
14
Parkinson’s Disease Key Products
15
Parkinson’s Disease Unmet Needs
16
Parkinson’s Disease Market Drivers and Barriers
17
Parkinson’s Disease Future Perspectives and Conclusion
18
Parkinson’s Disease Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Parkinson’s Disease drugs and therapies
Media ContactCompany Name: DelveInsight Business ResearchContact Person: Gaurav BoraEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting